Dr. Lee on Selecting a Treatment Approach for Neuroendocrine Tumors

Video

Yoomi Lee, MD, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.

Yoomi Lee, MD, a specialty care physician at Inova Medical Group, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.

The most important factors when selecting treatment are individualized for every patient, Lee says. For example, in a younger patient with low- to intermediate-grade neuroendocrine tumors, it is important to get the most benefit out of somatostatin (Reducin) analogue as possible.

Additionally, it is important not to utilize peptide receptor radionuclide therapy too early in treatment, due to a risk of the patient developing myelodysplastic syndrome of approximately 2%. This risk is a significant concern for young patients who are expected to have a long survival, Lee concludes.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ilyas Sahin, MD
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Riccardo Lencioni, MD, FSIR, EBIR
Manish A. Shah, MD
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Michael J. Overman, MD, The University of Texas MD Anderson Cancer Center,
John Michael Bryant, MD,
Jacob Shreve, MD, MS, hematology/oncology fellow, Mayo Clinic